Patrys Ltd (ASX: PAB) Share Price and News

Dr. Campbell has over 30 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of Australian and international biotechnology companies. Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX: CXS), where, as a member of the executive team he helped transform a research based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M. Dr. Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. Dr Campbell chairs the board of Australia's peak industry body for biotechnology, AusBiotech.

Mr. Stork was the Managing Director of Stork Holdings Ltd, an Investment Holding company in the Canadian technology start-up sector. Mr. Stork was on the Board of Governors of the University of Waterloo. He is chair of Risk Committee.

Mr Ross has over 10 years of experience in accounting and secretarial services for ASX listed companies. His experience includes ASX compliance, corporate governance control and implementation, statutory financial reporting, shareholder meeting requirements, capital raising management, and board and secretarial support.

Dr. Klein has a track record as an executive over more than 20 years in the oncology and biopharmaceutical industry. She is currently on the Board of Directors for Argenx, a dual-listed (Euronext Brussels and NASDAQ), clinical-stage therapeutic antibody company developing novel drugs in severe autoimmune disease. She is also on the Board of Frontier Medicines; Shasqi and ONA Therapeutics She was previously on the Board of Directors of F-Star Therapeutics, Jiya Acquisition Corp, a special purpose acquisition company (SPAC) affiliated with Samsara BioCapital, Sardona and I-MAB. Dr. Klein is the Principal and Founder of PMK BioResearch, which offers strategic consulting in oncology drug development. Other current directorships: Argenx (arGEN-X ADS (NASD)), Argenx (arGENX (EURONEXT), Shasqi. Former directorships (last 3 years): F-star Therapeutics (NASDAQ: FSTX), I-MAB, Sardona, Jiya Acquisition Corp.

Dr Gittleson is the former Chief Medical Officer of CSL Limited with more than 20 years of experience in pharmaceutical development in Australia and the USA. Dr Gittleson's expertise spans aspects of the pharmaceutical industry, from drug development and clinical research through to strategic planning and executive management. Dr Gittleson has been involved in drug development programs across a range of different therapeutic areas, and has worked with regulators in key markets such as the US, EU, Asia Pacific, Japan and South America. Dr Gittleson is member of Risk Committee.

-

-